** Shares of heart company Anteris Technologies slide 12.3% to $5.26 in their Nasdaq debut

** Stock opened for trading at $6, valuing the company at $215.6 mln

** AVR sold 14.8 mln shares in its New York IPO at $6/shr to raise $88.8 mln

** Offering priced at a 11.5% discount to the Dec. 5 closing price of its shares on the Australian Securities Exchange

** TD Cowen, Barclays and Cantor were the joint book-running managers for the offering

** AVR will use the proceeds to fund the development of its transcatheter heart valve, among other purposes

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))